Showing results (391-400 of 425) with videos related to
Sort By:
Pageof 43
JAMA|October 9, 2013
Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trialJudy C Boughey, Vera J Suman, Elizabeth A Mittendorf, et al.Journal of Immunology (Baltimore, Md. : 1950)|October 30, 2012
Broad cross-presentation of the hematopoietically derived PR1 antigen on solid tumors leads to susceptibility to PR1-targeted immunotherapyGheath Alatrash, Elizabeth A Mittendorf, Anna Sergeeva, et al.Nature Medicine|January 21, 2025
Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trialSherene Loi, Roberto Salgado, Giuseppe Curigliano, et al.Journal of the National Cancer Institute|April 12, 2023
Clonal hematopoiesis in older patients with breast cancer receiving chemotherapyChristina Mayerhofer, Mina S Sedrak, Judith O Hopkins, et al.JAMA Oncology|June 25, 2026
Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe TrialPaolo Tarantino, Tianyu Li, Esther Ritah Ogayo, et al.Cell|April 21, 2022
Quiescent cancer cells resist T cell attack by forming an immunosuppressive nichePilar Baldominos, Alex Barbera-Mourelle, Olga Barreiro, et al.Cell Reports|May 16, 2025
The impact of breast radiotherapy on the tumor genome and immune ecosystemAislyn Schalck, Tuan Tran, Jianzhuo Li, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2019
The Immune Microenvironment in Hormone Receptor-Positive Breast Cancer Before and After Preoperative ChemotherapyAdrienne G Waks, Daniel G Stover, Jennifer L Guerriero, et al.Nature Communications|September 22, 2021
Molecular correlates of response to eribulin and pembrolizumab in hormone receptor-positive metastatic breast cancerTanya E Keenan, Jennifer L Guerriero, Romualdo Barroso-Sousa, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2022
Molecular Characterization and Prospective Evaluation of Pathologic Response and Outcomes with Neoadjuvant Therapy in Metaplastic Triple-Negative Breast CancerClinton Yam, Nour Abuhadra, Ryan Sun, et al.Pageof 43